Genetic architecture and polygenic prediction of self-reported response to selective serotonin reuptake inhibitors in individuals with depression: a genome-wide meta-analysis

Selective serotonin reuptake inhibitors (SSRIs) are first-line treatments for depression, but response is highly variable, and no robust genetic predictors have been identified. We conducted a genome-wide association meta-analysis of self-reported SSRI response in 62,879 individuals of European ancestry with depression (72.6% responders) across six cohorts (seven datasets), followed by gene-set, transcriptomic, proteomic, drug-target and polygenic score (PGS) analyses. SNP-based heritability was modest but significant (h 2 = 3.1%, SE = 1.4%) with no genome-wide significant variants detected. Gene-set analyses implicated gamma-aminobutyric acid (GABA)ergic and glutamatergic neurotransmission, and a gene involved in glutamate transport ( SLC17A6 ) showed consistent sub-threshold evidence across pathway, transcriptomic and proteomic analyses. Drug-target enrichment for hypnotics, anxiolytics and general anesthetics further supported the GABAergic signal. A leave-one-out PGS from the discovery meta-analysis was associated with self-reported SSRI response in independent cohorts (meta-analysis OR = 1.05, 95% CI 1.02—1.08, p = 0.002). Higher PGS for depression, attention-deficit/hyperactivity disorder (ADHD), anxiety, post-traumatic stress disorder (PTSD), autism, addiction and schizophrenia were associated with lower odds of reported SSRI response, with ADHD, PTSD, autism and addiction remaining after adjustment for depression PGS. In contrast, educational attainment PGS was associated with better SSRI response. Self-reported SSRI response captures genetic insights relevant to antidepressant response, implicating GABAergic and glutamatergic neurotransmission. Individuals with higher genetic loading for psychiatric conditions report poorer response, and higher genetic loading for educational attainment PGS a better reported response. Although larger studies are needed to identify specific variants, self-report offers a practical, patient-centered and scalable route to collect the larger samples required.

Authors

Institutions

Publication Details

Journal
medRxiv
Published
2026-11-12
DOI
https://doi.org/10.64898/2026.11.11.26367161
Primary Topic
Genetic Associations and Epidemiology
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Genetic architecture and polygenic prediction of self-reported response to selective serotonin reuptake inhibitors in individuals with depression: a genome-wide meta-analysis

Gerome D. Breen, Cameron James Watson, Michelle Kamp, Madhurbain Singh et al.
medRxiv
Genetic Associations and Epidemiology
preprint

Genetic architecture and polygenic prediction of self-reported response to selective serotonin reuptake inhibitors in individuals with depression: a genome-wide meta-analysis

Gerome D. Breen, Cameron James Watson, Michelle Kamp, Madhurbain Singh, Cathryn M. Lewis, Brittany L. Mitchell, NIHR BioResource, Jonathan R. I. Coleman, Sang Hyuck Lee, Chris Wai Hang Lo, Jodi T. Thomas, Oliver Pain, Ke Hu
preprint en

Abstract

Selective serotonin reuptake inhibitors (SSRIs) are first-line treatments for depression, but response is highly variable, and no robust genetic predictors have been identified. We conducted a genome-wide association meta-analysis of self-reported SSRI response in 62,879 individuals of European ancestry with depression (72.6% responders) across six cohorts (seven datasets), followed by gene-set, transcriptomic, proteomic, drug-target and polygenic score (PGS) analyses. SNP-based heritability was modest but significant (h 2 = 3.1%, SE = 1.4%) with no genome-wide significant variants detected. Gene-set analyses implicated gamma-aminobutyric acid (GABA)ergic and glutamatergic neurotransmission, and a gene involved in glutamate transport ( SLC17A6 ) showed consistent sub-threshold evidence across pathway, transcriptomic and proteomic analyses. Drug-target enrichment for hypnotics, anxiolytics and general anesthetics further supported the GABAergic signal. A leave-one-out PGS from the discovery meta-analysis was associated with self-reported SSRI response in independent cohorts (meta-analysis OR = 1.05, 95% CI 1.02—1.08, p = 0.002). Higher PGS for depression, attention-deficit/hyperactivity disorder (ADHD), anxiety, post-traumatic stress disorder (PTSD), autism, addiction and schizophrenia were associated with lower odds of reported SSRI response, with ADHD, PTSD, autism and addiction remaining after adjustment for depression PGS. In contrast, educational attainment PGS was associated with better SSRI response. Self-reported SSRI response captures genetic insights relevant to antidepressant response, implicating GABAergic and glutamatergic neurotransmission. Individuals with higher genetic loading for psychiatric conditions report poorer response, and higher genetic loading for educational attainment PGS a better reported response. Although larger studies are needed to identify specific variants, self-report offers a practical, patient-centered and scalable route to collect the larger samples required.

medRxiv
King's College London (GB), QIMR Berghofer Medical Research Institute (AU)
NIHR Maudsley Biomedical Research Centre
Good health and well-being
Genetic Associations and Epidemiology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon